DE60009931T2 - Muscarin-antagonisten - Google Patents
Muscarin-antagonisten Download PDFInfo
- Publication number
- DE60009931T2 DE60009931T2 DE60009931T DE60009931T DE60009931T2 DE 60009931 T2 DE60009931 T2 DE 60009931T2 DE 60009931 T DE60009931 T DE 60009931T DE 60009931 T DE60009931 T DE 60009931T DE 60009931 T2 DE60009931 T2 DE 60009931T2
- Authority
- DE
- Germany
- Prior art keywords
- etoac
- formula
- compounds
- compound according
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 0 C*C1(C)OCCO1 Chemical compound C*C1(C)OCCO1 0.000 description 5
- RKCFVYYSKVELRI-UHFFFAOYSA-N Brc1ccc(C2(C3CCNCC3)OCCO2)cc1 Chemical compound Brc1ccc(C2(C3CCNCC3)OCCO2)cc1 RKCFVYYSKVELRI-UHFFFAOYSA-N 0.000 description 1
- DHWSLAIXSIOEOQ-UHFFFAOYSA-N Brc1ccc(CC2CCNCC2)cc1 Chemical compound Brc1ccc(CC2CCNCC2)cc1 DHWSLAIXSIOEOQ-UHFFFAOYSA-N 0.000 description 1
- ROUYFJUVMYHXFJ-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1=O)=O ROUYFJUVMYHXFJ-UHFFFAOYSA-N 0.000 description 1
- UMXDVRQPESFRTN-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1N1CC(Cc(cc2)ccc2Br)CC1)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1N1CC(Cc(cc2)ccc2Br)CC1)=O UMXDVRQPESFRTN-UHFFFAOYSA-N 0.000 description 1
- UPZFLZYXYGBAPL-UHFFFAOYSA-N CCC1(C)OCCO1 Chemical compound CCC1(C)OCCO1 UPZFLZYXYGBAPL-UHFFFAOYSA-N 0.000 description 1
- ATHCBVXLLXDDKU-HIFPTAJRSA-N C[C@@H](CC1)N=CC1SC1C=CC=C([CH2+])C1 Chemical compound C[C@@H](CC1)N=CC1SC1C=CC=C([CH2+])C1 ATHCBVXLLXDDKU-HIFPTAJRSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
- C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40139199A | 1999-09-22 | 1999-09-22 | |
| US401391 | 1999-09-22 | ||
| PCT/US2000/018358 WO2001021590A1 (en) | 1999-09-22 | 2000-07-05 | Muscarinic antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60009931D1 DE60009931D1 (de) | 2004-05-19 |
| DE60009931T2 true DE60009931T2 (de) | 2005-04-07 |
Family
ID=23587566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60009931T Expired - Lifetime DE60009931T2 (de) | 1999-09-22 | 2000-07-05 | Muscarin-antagonisten |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1214299B1 (https=) |
| JP (1) | JP2003509494A (https=) |
| CN (1) | CN1167682C (https=) |
| AR (1) | AR025459A1 (https=) |
| AT (1) | ATE264301T1 (https=) |
| AU (1) | AU5786300A (https=) |
| CA (1) | CA2384018C (https=) |
| CO (1) | CO5180624A1 (https=) |
| DE (1) | DE60009931T2 (https=) |
| ES (1) | ES2215055T3 (https=) |
| HK (1) | HK1043590A1 (https=) |
| MX (1) | MXPA02003136A (https=) |
| PE (1) | PE20010649A1 (https=) |
| WO (1) | WO2001021590A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL117149A0 (en) * | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
| DE60213629T2 (de) * | 2001-10-10 | 2007-10-18 | Schering Corp. | Piperidinverbindungen als muscarinantagonisten |
| WO2004069828A1 (ja) * | 2003-02-04 | 2004-08-19 | Mitsubishi Pharma Corporation | ピペリジン化合物およびその医薬用途 |
| EA202092673A3 (ru) | 2010-02-09 | 2021-05-31 | Дзе Джонс Хопкинс Юниверсити | Способы и композиции для улучшения когнитивной функции |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| WO2014122474A1 (en) | 2013-02-07 | 2014-08-14 | Takeda Pharmaceutical Company Limited | Piperidin-1 -yl and azepin-1 -yl carboxylates as muscarinic m4 receptor agonists |
| WO2014144663A1 (en) | 2013-03-15 | 2014-09-18 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| AU2014228512A1 (en) | 2013-03-15 | 2015-10-01 | Agenebio, Inc. | Methods and compositions for improving cognitive function |
| CA2986598C (en) | 2015-05-22 | 2023-09-26 | Agenebio, Inc. | Extended release pharmaceutical compositions of levetiracetam |
| EP3371164B1 (en) | 2015-11-06 | 2022-03-16 | Neurocrine Biosciences, Inc. | N-[2-(1-benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1-carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases |
| EP4069367B1 (en) | 2019-12-06 | 2024-05-15 | Neurocrine Biosciences, Inc. | Muscarinic receptor 4 antagonists and methods of use |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5691323A (en) * | 1995-05-12 | 1997-11-25 | Merck & Co., Inc. | Muscarine antagonists |
| IL117149A0 (en) * | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
| US5889006A (en) * | 1995-02-23 | 1999-03-30 | Schering Corporation | Muscarinic antagonists |
| US6066636A (en) * | 1998-06-30 | 2000-05-23 | Schering Corporation | Muscarinic antagonists |
| AU756484B2 (en) * | 1998-06-30 | 2003-01-16 | Schering Corporation | Muscarinic antagonists |
-
2000
- 2000-07-05 HK HK02105117.5A patent/HK1043590A1/zh unknown
- 2000-07-05 DE DE60009931T patent/DE60009931T2/de not_active Expired - Lifetime
- 2000-07-05 AT AT00943386T patent/ATE264301T1/de not_active IP Right Cessation
- 2000-07-05 EP EP00943386A patent/EP1214299B1/en not_active Expired - Lifetime
- 2000-07-05 JP JP2001524970A patent/JP2003509494A/ja active Pending
- 2000-07-05 ES ES00943386T patent/ES2215055T3/es not_active Expired - Lifetime
- 2000-07-05 CA CA002384018A patent/CA2384018C/en not_active Expired - Fee Related
- 2000-07-05 AU AU57863/00A patent/AU5786300A/en not_active Abandoned
- 2000-07-05 CN CNB008130795A patent/CN1167682C/zh not_active Expired - Fee Related
- 2000-07-05 WO PCT/US2000/018358 patent/WO2001021590A1/en not_active Ceased
- 2000-07-05 MX MXPA02003136A patent/MXPA02003136A/es unknown
- 2000-08-31 PE PE2000000890A patent/PE20010649A1/es not_active Application Discontinuation
- 2000-08-31 AR ARP000104540A patent/AR025459A1/es unknown
- 2000-08-31 CO CO00065610A patent/CO5180624A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ES2215055T3 (es) | 2004-10-01 |
| CN1374949A (zh) | 2002-10-16 |
| AU5786300A (en) | 2001-04-24 |
| WO2001021590A1 (en) | 2001-03-29 |
| EP1214299B1 (en) | 2004-04-14 |
| AR025459A1 (es) | 2002-11-27 |
| DE60009931D1 (de) | 2004-05-19 |
| CA2384018C (en) | 2010-01-12 |
| CN1167682C (zh) | 2004-09-22 |
| CO5180624A1 (es) | 2002-07-30 |
| HK1043590A1 (zh) | 2002-09-20 |
| CA2384018A1 (en) | 2001-03-29 |
| EP1214299A1 (en) | 2002-06-19 |
| MXPA02003136A (es) | 2002-09-30 |
| ATE264301T1 (de) | 2004-04-15 |
| PE20010649A1 (es) | 2001-06-19 |
| JP2003509494A (ja) | 2003-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69733478T2 (de) | Ether-muskarinantagonisten | |
| US6294554B1 (en) | Muscarinic antagonists | |
| DE69631370T2 (de) | Benzylpiperidine und -piperazine als muscarinantagonisten | |
| DE69111029T2 (de) | Kondensierte heterocyclische Verbindungen, ihre Herstellung und Verwendung. | |
| DE69103206T2 (de) | Neue Derivate des Aminopiperidins, Aminopyrrolidins und des Aminoperhydroazepins, Verfahren zur Herstellung und diese enthaltende Arzneimittel. | |
| DE69534213T2 (de) | Therapeutisch wirksame Heterocyclen | |
| DE69717109T2 (de) | 1,4-disubstituierte piperdine als muskarin-antagonisten | |
| DE69715865T2 (de) | Muscarin-antagonisten | |
| DE2824064A1 (de) | Phthalazin-derivate, ihre herstellung und solche derivate enthaltende arzneimittel | |
| CH649527A5 (de) | 1,2-diaminocyclobuten-3,4-dione, verfahren zu deren herstellung und pharmazeutische mittel, die diese verbindungen enthalten. | |
| EP2060569A1 (de) | 3-[(2-{[4-Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat-Hemihydrat und dessen Verwendung als Arzneimittel | |
| TW201041868A (en) | Anthelmintic agents and their use | |
| JP2007297410A (ja) | ムスカリンアンタゴニスト | |
| DE69919171T2 (de) | Muskarin-rezeptor antagonisten | |
| EP0505868A2 (de) | N-Acyl-alpha-aminosäurederivate | |
| DE60009931T2 (de) | Muscarin-antagonisten | |
| DE69613457T2 (de) | 5-(4-subst.-piperidinyl-1)-3-aryl-pentansäure derivate als tachykinin rezeptor antagonisten | |
| DE68910999T2 (de) | 1,2,3,4-Tetrahydroisoquinoline, Verfharen zu ihrer Herstellung und ihre Verwendung als Kappa-Rezeptor Agonisten. | |
| DE69214588T2 (de) | Methanoanthracene als Dopaminantagonisten | |
| DE69733427T2 (de) | Tetrahydrobezindol derivate | |
| DE1117584B (de) | Verfahren zur Herstellung von Phentiazinderivaten | |
| DE69732762T2 (de) | Indanderivate für antipsychotische mittel | |
| DE69916073T2 (de) | Triazolopyridine für behandlung von thrombosen | |
| DE2847621A1 (de) | Phthalazin-derivate, verfahren zu ihrer herstellung und solche derivate enthaltende arzneimittel | |
| DE68916979T2 (de) | Alkylen-diamine. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8332 | No legal effect for de | ||
| 8370 | Indication related to discontinuation of the patent is to be deleted | ||
| 8364 | No opposition during term of opposition |